Isolation and characterization of squamous carcinoma cells resistant to photodynamic therapy.

Photodynamic therapy (PDT) employing methyl δ-aminolevulinic acid (Me-ALA), as a precursor of the photosensitizer protoporphyrin IX (PpIX), is used for the treatment of non melanoma cutaneous cancer (NMCC). However, one of the problems of PDT is the apparition of resistant cell populations. The aim of this study was to isolate and characterize squamous carcinoma cells SCC-13 resistant to PDT with Me-ALA. The SCC-13 parental population was submitted to successive cycles of Me-ALA-PDT and 10 resistant populations were finally obtained. In parental and resistant cells there were analyzed the cell morphology (toluidine blue), the intracellular PpIX content (flow cytometry) and its localization (fluorescence microscopy), the capacity of closing wounds (scratch wound assay), the expression of cell-cell adhesion proteins (E-cadherin and ß-catenin), cell-substrate adhesion proteins (ß1-integrin, vinculin and phospho-FAK), cytoskeleton proteins (α-tubulin and F-actin) and the inhibitor of apoptosis protein survivin, in the activated form as phospho-survivin (indirect immunofluorescence and Western blot). The results obtained indicate that resistant cells showed a more fibroblastic morphology, few differences in intracellular content of the photosensitizer, higher capacity of closing wounds, higher number of stress fibers, more expression of cell-substrate adhesion proteins and higher expression of phospho-survivin than parental cells. These distinctive features of the resistant cells can provide decisive information to enhance the efficacy of Me-ALA applications in clinic dermatology.

Pharmacokinetic, toxicological and phototherapeutic studies of phthalocyanine ZnPcCF3.

Photodynamic therapy (PDT) is an alternative modality for cancer therapy. It induces neoplasic cells death through photoachievable sensitizers. The aim of this work was to evaluate the pharmacokinetic, toxic and phototherapeutic effects of the phthalocyanine ZnPcCF(3) in a Balb/c mice tumor model. Biodistribution studies were carried out by intraperitoneal injection of 0.2mg/kg ZnPcCF(3). Histological studies and serum biochemical parameters were used to evaluate hepatic and renal toxicity and functionality. After tumor irradiation (210J/cm(2)), an analysis of tumor necrosis degree was used to evaluate the phototherapeutic effects. It was measured at 1, 2, 3 and 4 days after PDT. Vital staining was performed by intraperitoneal injection of 0.35ml 1% Evans Blue solution. Six hours later, tumors were excised and examined. The unstained area was attributed to necrotic tissue, whereas the stained area showed tissue with preserved blood supply. ZnPcCF(3) was accumulated in spleen, liver and duodenum. It suggests that ZnPcCF(3) is eliminated from the body via bile-gut. The phthalocyanine was not found in brain, therefore, it would not cross the blood-brain barrier, thus toxicity risk in the central nervous system is not probable. Moreover, ZnPcCF(3) does not accumulate in skin, it would eliminate cutaneous photosensitizing risks. The dose of 0.2mg/kg ZnPcCF(3) resulted in a low acute toxicity with revertible damages, which indicates that this dose can be used for PDT. The tumor death was of 89% 4 days after PDT. It indicates that ZnPcCF(3) would be effective in PDT.